Adma Biologics, Inc.
ADMA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001368514
No open-market purchases or sales by Adma Biologics, Inc. insiders were filed in the last 90 days; 322 institutions reported holding it in 13F filings for Q2 2026, worth $1.70B in total; superinvestors Duquesne Family Office and Fundsmith hold it.
Q2 2022 vs. Q1 2022
How the institutions holding Adma Biologics, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Of which not filed for Q2 2022 | Q2 2022 | Change |
|---|---|---|---|---|
| Holders | 105 | 1 | 113 | +9 |
| Shares | 104.9M | 11.5K | 119.2M | +14.3M (+13.7%) |
| Value | $189.9M | $21.0K | $236.0M | +$46.2M (+24.3%) |
1 institution that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (35)
Institutions that held Adma Biologics, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
Sold out (26)
Institutions that held Adma Biologics, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
Not filed for Q2 2022 yet (1)
Institutions that held Adma Biologics, Inc. at the end of Q1 2022 and haven't filed a 13F for Q2 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Livingston Group Asset Management CO (operating as Southport Capital Management) | 11,500 | $21.0K |